title: Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.
abstract: OBJECTIVE
  Pharmacogenetic influences on therapeutic response to neuroleptic treatment are poorly understood. This study investigates the association of response to short-term haloperidol treatment with a Taq I polymorphism in the DRD2 gene.
  
  
  METHODS
  Fifty-seven patients with acute psychosis were treated with haloperidol for up to 28 days. Improvement and response were measured by using the Positive and Negative Syndrome SCALE: Forty-one patients were homozygous for allele 2, and 16 were heterozygous.
  
  
  RESULTS
  Heterozygous patients showed a greater improvement in positive, but not in negative, symptoms on all treatment days than patients homozygous for allele 2. Differences in improvement of positive symptoms reached statistical significance on days 14, 21, and 28. On treatment day 14, 10 (62.5%) of 16 heterozygous patients had at least 50% improvement of positive symptoms, compared with 11 (28.9%) of 38 homozygous patients.
  
  
  CONCLUSIONS
  These results support the hypothesis that genetic variations in the DRD2 gene may influence the individual response to antipsychotics.
authors.affiliation: Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany. schaefer@chante.de
authors.forename: M
authors.initials: M
authors.lastname: Schäfer
authors.forename: D
authors.initials: D
authors.lastname: Rujescu
authors.forename: I
authors.initials: I
authors.lastname: Giegling
authors.forename: A
authors.initials: A
authors.lastname: Guntermann
authors.forename: A
authors.initials: A
authors.lastname: Erfurth
authors.forename: B
authors.initials: B
authors.lastname: Bondy
authors.forename: H J
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000188:drug therapy; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D017448:Receptors, Dopamine D2; D006220:Haloperidol